All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Since it was first reported in 1961 by Sarles *et al* \[[@pone.0130466.ref001]\] and was termed as autoimmune pancreatitis (AIP) in 1995 by Yoshida *et al* \[[@pone.0130466.ref002]\], AIP has gradually attracted attention in recent years. Nowadays, two subtypes of AIP are known---type 1 is a multi-organ disease associated with IgG4 while type 2 appears to be a pancreas-specific disorder \[[@pone.0130466.ref003]\]. In recent years, diagnostic criteria of AIP have been proposed in Japan, United States, Korea and Italy, and an International Consensus Diagnostic Criteria (ICDC) for AIP has been reached \[[@pone.0130466.ref004]\].

China has a high prevalence of pancreatic disease \[[@pone.0130466.ref005]\], and if the prevalence rate of AIP in Japan (2.2 per 100,000 populations) was used, the estimated amount of AIP patients would be 29 thousand \[[@pone.0130466.ref006]\]. However, there have been only a few reports about AIP from China \[[@pone.0130466.ref007]--[@pone.0130466.ref010]\]. In this study, we collected all well-designed clinical studies of AIP from China, and provided comprehensive data on the clinical presentation, diagnosis and treatment of Chinese AIP patients.

Methods {#sec007}
=======

Strategy, criteria, and procedures for the literature search {#sec008}
------------------------------------------------------------

We conducted a systematic literature search of PubMed, Web of Science and Chinese literature database including Wanfang Data and CNKI on June 20, 2014, and all publications related to AIP between January 2006 and June 2014 were retrieved. Indexing terms used for searching were autoimmune pancreatitis, IgG4-related disease, lymphoplasmacytic sclerosing pancreatitis, idiopathic duct centric pancreatitis, chronic pancreatitis with autoimmune diseases. Inclusion and exclusion criteria were delineated before commencement of the literature search. Inclusion criteria included: (1) cases were Chinese patients; (2) the diagnostic criteria of AIP were clearly defined and consistent with the current accepted ones, which included ICDC \[[@pone.0130466.ref004]\] and criteria proposed by Japan \[[@pone.0130466.ref011], [@pone.0130466.ref012]\], Mayo Clinic \[[@pone.0130466.ref013]\], Korea \[[@pone.0130466.ref014]\], and Asian (Korea-Japan symposium) \[[@pone.0130466.ref015]\]; (3) The number of patients in single article is ≥ 10; (4) if multiple articles were from the same institution, the one with most patients were selected. All articles other than original contributions, such as case reports, reviews, meta-analyses, editorials and letters were excluded. This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement checklist ([S1 PRISMA Checklist](#pone.0130466.s001){ref-type="supplementary-material"}).

Definitions {#sec009}
-----------

In order to include all relevant articles without loss of the fundamental meanings of the terms, clinical presentation and extrapancreatic manifestation were defined in a relatively broad way. Abdominal symptoms included abdominal pain or discomfort. Because the diagnostic criteria for acute pancreatitis were not clearly given in most of the literature, the presentation of acute pancreatitis mentioned in some articles was classified as abdominal symptoms. Bile duct involvement means bile duct stricture, divided into lower part of the common bile duct stricture and hilar/intrahepatic bile ducts stricture. Because ICDC clearly defines the subtypes of AIP, the proportion of type 1 and type 2 AIP was estimated according to studies adopting ICDC as criteria.

Data extraction from eligible articles {#sec010}
--------------------------------------

Data on the clinical presentations, laboratory tests, imaging examinations, pathological examinations, treatment and outcomes of the patients were retrieved. Missing data or indeterminate definitions were resolved by direct contact with authors if possible and were otherwise considered not available. Two authors (Q.Q.M., L.X.) determined the relevant original articles and extracted the data independently, whereas the third author (W.Y.L) checked the results. If a disagreement existed, the relevant programs were repeated until a consensus was achieved among the authors.

Statistical analysis {#sec011}
--------------------

Descriptive analysis or meta-analysis was conducted to provide the overall data of clinical presentation, laboratory test, imaging examination, pathological examination, treatment and outcome of the patients. In the meta-analysis, Cochran's Q test was used to test the heterogeneity of results across studies, and I^2^ was calculated to quantify the heterogeneity among studies. If the p value was less than 0.10 (Cochran's Q test), the results were considered heterogeneous and random-effects model was used to obtain the pooled estimates. Otherwise, fixed-effects model was applied. The potential presence of publication bias was evaluated statistically by the Begg-Mazumdar's and Egger's test. Meta-analysis was performed with StatsDirect Statistical software, version 2.7.8 (StatsDirect Ltd, Altrincham, UK).

Results {#sec012}
=======

A total of 26 articles (5 English-language and 21 Chinese-language articles) were enrolled in the study (\[[@pone.0130466.ref008], [@pone.0130466.ref009], [@pone.0130466.ref016]\] and [S1 File](#pone.0130466.s002){ref-type="supplementary-material"}). The detailed search procedures are outlined in *[Fig 1](#pone.0130466.g001){ref-type="fig"}*. The detailed data related to diagnostic criteria for AIP are outlined in [Table 1](#pone.0130466.t001){ref-type="table"}. In the 5 studies which adopted ICDC as criteria, the proportion of type 2 AIP was 4.7% (8/171). Detailed data and forest plots for all of the variables are listed in [S2 File](#pone.0130466.s003){ref-type="supplementary-material"}.

![Flow chart for literature search on original articles about Chinese AIP patients.](pone.0130466.g001){#pone.0130466.g001}

10.1371/journal.pone.0130466.t001

###### The diagnostic criteria for AIP adopted by 26 studies from China (N = 706)^a^.

![](pone.0130466.t001){#pone.0130466.t001g}

  Diagnostic Criteria              No.of studies (%)   No. of cases (%)
  -------------------------------- ------------------- ------------------
  Japanese criteria                7 (26.9)            126 (17.8)
  Mayo Clinic\'s HISORt criteria   3 (11.5)            150 (21.2)
  Korean criteria                  2 (7.7)             30 (4.2)
  Asian diagnostic criteria        12(46.2)            416(58.9)
  ICDC                             5(19.2)             171(24.2)

^a^ Different kinds of diagnostic criteria for AIP were adopted by three studies

Demographics and Clinical Presentation {#sec013}
--------------------------------------

Among the 706 AIP patients, 577 were men (male/female: 4.47:1) and the range of mean/median age of the patients was 48.6--67.0 years old.

Clinical presentation of AIP patients were described in all 26 articles. Obstructive jaundice is the most common presentation (pooled rate: 63.4%, 95%CI: 55.4%--71.0%). Abdominal symptoms was another common presentation (pooled rate: 62.3%, 95%CI: 52.4%--71.7%). The other presentations included weight loss (pooled rate: 45.1%, 95%CI: 34.8%--55.6%) and diabetes mellitus (pooled rate: 26.9%, 95%CI: 18.3%--36.4%). Moreover, pancreatic mass or enlargement was found incidentally by imaging examinations in some asymptomatic patients (pooled rate: 2.9%, 95%CI: 1.6%--4.5%) ([Table 2](#pone.0130466.t002){ref-type="table"}).

10.1371/journal.pone.0130466.t002

###### Pooled positive rate of various manifestation in Chinese AIP patients.
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                                                                                       Tests of Heterogeneity   Tests of Publication Bias                     
  -------------------------------------------------- ---- --------- ------------------ ------------------------ --------------------------- ------ ---------- ----------
  Clinical presentation                                                                                                                                       
      Obstructive jaundice                           26   432/706   63.4(55.4--71.0)   116.89                   \<0.0001                    78.6   0.1932     0.0185
      Abdominal symptoms                             26   382/706   62.3(52.4--71.7)   178.82                   \<0.0001                    86     0.3655     0.8228
      Weight loss                                    18   206/495   45.1(34.8--55.6)   94.18                    \<0.0001                    81.9   0.2107     0.0008
      Diabetes mellitus                              23   157/595   26.9(18.3--36.4)   139.53                   \<0.0001                    84.2   0.4918     \<0.0001
      Asymptomatic patients                          26   22/706    2.9(1.6--4.5)      34.23                    0.103                       27     \<0.0001   0.1127
  Extrapancreatic manifestation                                                                                                                               
      Lower part of the common bile duct stricture   19   290/473   62.3(49.9--73.9)   131.11                   \<0.0001                    86.3   0.7792     0.0086
      Hilar/intra hepatic bile ducts stricture       17   32/409    3.6(1.1--7.3)      45.66                    0.0001                      65     0.0063     0.7545
      Abdominal lymph nodes enlargement              20   99/420    19.7(9.2--32.9)    190.81                   \<0.0001                    90     0.0007     0.0139
      Swelling salivary gland                        18   51/466    12.0(5.7--20.3)    98.38                    \<0.0001                    82.7   \<0.0001   0.0022
      Swelling lacrimal gland                        18   12/504    2.7(1.0--5.1)      32.33                    0.0137                      47.4   \<0.0001   0.0165
      Symptom similar with Sjögren syndrome          12   26/274    8.9(4.2--15.1)     29.24                    0.0021                      62.4   0.0088     0.0038
      Interstitial nephritis                         18   29/515    4.6(1.9--8.5)      52.57                    \<0.0001                    67.7   0.0003     0.0361
      Retroperitoneal fibrosis                       14   15/464    3.4(2.0--5.2)      16.84                    0.2066                      22.8   0.0546     0.1481
      Interstitial lung disease                      16   15/471    3.0(1.0--6.0)      36.92                    0.0013                      59.4   0.0001     0.0844
      Ulcerative colitis                             14   4/446     1.6(0.6--2.9)      4.19                     0.989                       0      0.0748     0.7726

The details of extrapancreatic manifestation were reported in 20 articles. Biliary involvement was the most common extrapancreatic manifestation, which included lower part of the common bile duct stricture (pooled rate: 62.3%, 95%CI: 49.9%--73.9%) and hilar/intra hepatic bile ducts stricture (pooled rate: 3.6%, 95%CI: 1.1%--7.3%). Abdominal lymph nodes enlargement is a relatively common manifestation (pooled rate: 19.7%, 95%CI: 9.2%--32.9%). Fifty-one (pooled rate: 12.0%, 95%CI: 5.7%--20.3%) patients and 12 (pooled rate: 2.7%, 95%CI: 1.0%--5.1%) patients have swelling salivary gland and swelling lacrimal gland, respectively, while 26 (pooled rate: 8.9%, 95%CI: 4.2%--15.1%) patients have symptom similar with Sjögren syndrome. Other extrapancreatic manifestations included interstitial nephritis (pooled rate: 4.6%, 95%CI: 1.9%--8.5%), retroperitoneal fibrosis (pooled rate: 3.4%, 95%CI: 2.0%--5.2%), interstitial lung disease (pooled rate: 3.0%, 95%CI: 1.0%--6.0%) and ulcerative colitis (pooled rate: 1.6%, 95%CI: 0.6%--2.9%) ([Table 2](#pone.0130466.t002){ref-type="table"}).

Imaging examinations {#sec014}
--------------------

The general manifestation of pre-treatment computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound examination was reported in 627 patients from 25 articles. Among these 627 patients, 337 (53.8%) were classified into diffuse-type, 261 (41.6%) were focal-type and 29 (4.6%) with atypical imaging manifestation could not be clearly classified into either type. Most lesions of focal-type were located in the head (74.4%, 174/234), and the other were located in the body (11.5%, 27/234) and the tail (14.1%, 33/234). Delayed enhancement was the most typical manifestation (272/286, pooled rate: 94.4%, 95%CI: 88.5%--98.2%). Moreover, rim-like enhancement is found in considerable part of patients (226/445, pooled rate: 62.7%, 95%CI: 48.3%--76.0%). Calcification in parenchyma (18/487, pooled rate: 3.9%, 95%CI: 1.8%--6.8%) and pancreatic pseudocysts (14/487, pooled rate: 3.4%, 95%CI: 2.0%--5.1%) were rare manifestations ([Table 3](#pone.0130466.t003){ref-type="table"}).

10.1371/journal.pone.0130466.t003

###### Pooled positive rate of various imaging manifestations in Chinese AIP patients.
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                                                                            Tests of Heterogeneity   Tests of Publication Bias                     
  -------------------------------------- ---- --------- ------------------- ------------------------ --------------------------- ------ ---------- --------
  Parenchymal imaging                                                                                                                              
      Delayed enhancement                13   272/286   94.4 (88.5--98.2)   38.41                    0.0001                      68.8   \<0.0001   0.0018
      Rim-like enhancement               18   226/445   62.7 (48.3--76.0)   162.47                   \<0.0001                    89.5   0.3686     0.5849
      Calcification in parenchyma        21   18/487    3.9 (1.8--6.8)      39.94                    0.0051                      49.9   \<0.0001   0.0033
      Pancreatic pseudocysts             21   14/487    3.4 (2.0--5.1)      17.38                    0.6281                      0      0.0303     0.0394
  Ductal imaging                                                                                                                                   
      Stricture of the pancreatic duct   18   231/347   68.1 (49.3--84.3)   232.83                   \<0.0001                    92.7   0.0813     0.0035
      Dilation of pancreatic duct        19   64/367    13.8 (6.6--23.1)    101.00                   \<0.0001                    82.2   \<0.0001   0.0007
      Pancreatic duct calculi            20   6/460     1.9 (0.9--3.3)      11.97                    0.8869                      0      \<0.0001   0.2087

In the aspect of pancreatic duct, about two-thirds patients showed stricture of pancreatic duct (231/347, pooled rate: 68.1%, 95%CI: 49.3%--84.3%) and dilatation was also found in parts of patients (64/367, pooled rate: 13.8%, 95%CI: 6.6%--23.1%). Pancreatic duct calculi was rare manifestation (6/460, pooled rate: 1.9%, 95%CI: 0.9%--3.3%) ([Table 3](#pone.0130466.t003){ref-type="table"}).

Laboratory tests {#sec015}
----------------

Various serum markers were measured in different amount of patients ([Table 4](#pone.0130466.t004){ref-type="table"}). In 9 studies, the level of serum IgG4 exceeds the upper limit of normal in 170 of 195 patients (pooled rate: 86.0%, 95%CI: 74.2%--94.6%). The positive rates of IgG and IgE were 65.7% (257/391, pooled rate: 70.2%, 95%CI: 60.6%--79.1%) and 43.4% (49/113, pooled rate: 61.8%, 95%CI: 23.7%--92.9%), respectively.

10.1371/journal.pone.0130466.t004

###### Pooled positive rate of various serum markers in Chinese AIP patients.

![](pone.0130466.t004){#pone.0130466.t004g}

                                                                                      Tests of Heterogeneity   Tests of Publication Bias                   
  ------------------------------------------------- ---- --------- ------------------ ------------------------ --------------------------- ------ -------- --------
  IgG4 [^**a**^](#t004fn001){ref-type="table-fn"}   9    170/195   86.0(74.2--94.6)   31.71                    0.0001                      74.8   0.0446   0.0265
  IgG [^**b**^](#t004fn002){ref-type="table-fn"}    19   257/391   70.3(60.6--79.1)   74.87                    \<0.0001                    76     0.195    0.3595
  IgE [^**c**^](#t004fn003){ref-type="table-fn"}    4    49/113    61.8(23.7--92.9)   37.6                     \<0.0001                    91.9   0.75     0.7564
  γ-globulin                                        12   154/225   67.9(56.9--78.0)   34.67                    0.0003                      68.3   0.0138   0.0019
  Rheumatoid factor                                 6    34/110    35.7(20.7--52.2)   14.75                    0.0115                      66.1   0.2722   0.0517
  ANA [^**d**^](#t004fn005){ref-type="table-fn"}    13   83/266    33.3(24.8--42.4)   29.21                    0.0037                      58.9   0.0573   0.074
  ESR [^**e**^](#t004fn006){ref-type="table-fn"}    7    65/109    59.4(50.4--68.2)   10.20                    0.1163                      41.2   0.1668   0.0051
  CA19-9                                            18   178/411   41.5(34.9--48.3)   32.16                    0.0144                      47.1   0.9697   0.3708

^**a**^Immunoglobulin G4

^**b**^Immunoglobulin G

^**c**^Immunoglobulin E

A

^**d**^Anti-neutrophil antibody

^**e**^Erythrocyte sedimentation rate

Pathology {#sec016}
---------

In the 706 patients, pancreatic cytology specimens were obtained in 79 (11.2%) by endoscopic ultrasonography (EUS)-guided or CT-guided fine-needle aspiration (FNA) and no malignant or atypical cells were found. Pancreatic histology specimens were obtained from 220 (31.2%) patients by surgery. A total of 212 and 8 histology examinations supported the diagnosis of lymphoplasmacytic sclerosing pancreatitis and idiopathic duct-centric pancreatitis respectively. In the 66 patients (4 studies) receiving pancreatic immunohistochemical examination, marked IgG4 positive cells (\>10 cells / high-power fields \[HPF\]) were found in 58 (pooled rate: 88.7%, 95%CI: 65.2%--99.7%) patients.

Treatment and follow-up {#sec017}
-----------------------

Due to mimicked malignancy, nearly one third AIP patients received surgery (pooled rate: 29.7%, 95%CI: 18.1%--42.8%). Surgical procedures included pancreaticoduodenectomy (43.0%, 52/121), distal pancreatectomy with or without splenectomy (9.1%, 11/121), choledojejunostomy with the resection of hilar mass (1.6%, 2/121), biliary-entericanastomosis (27.3%, 33/121) and exploratory laparotomy (19.0%, 23/121).

Steroid treatment was given to most patients (pooled rate: 78.4%, 95%CI: 65.3%--89.1%). In the 272 patients with detailed regimen, a fixed dose (30mg or 40mg prednisone per day) were given as the initial dose to 206 (75.7%) patients, while a personalized initial dose (0.6mg/kg per day) were given to other 66 (24.3%) patients. After steroid therapy, most patients got remission (pooled rate: 96.2%, 95%CI: 94.0%--97.9%). In 269 patients receiving steroid treatment and having follow-up data, relapse occurred in 37 patients (pooled rate: 13.8%, 95%CI: 7.2%--22.0%) with the mean follow-up time ranging from 12 to 45 months. Repeated steroid treatment was given to most patients with relapse (pooled rate: 95.8%, 95%CI: 89.8%--99.3%) and obtained good remission outcome (pooled rate: 94.8%, 95%CI: 88.2%--98.8%) ([Table 5](#pone.0130466.t005){ref-type="table"}).

10.1371/journal.pone.0130466.t005

###### Pooled positive rate of treatment and prognosis in Chinese AIP patients.
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                                                                                 Tests of Heterogeneity   Tests of Publication Bias                     
  -------------------------------------------- ---- --------- ------------------ ------------------------ --------------------------- ------ ---------- --------
  Surgery treatment                            25   236/689   29.7(18.1--42.8)   317.31                   \<0.0001                    92.4   0.0082     0.3828
  Steroid treatment                            21   383/603   78.4(65.3--89.1)   262.80                   \<0.0001                    92.4   0.013      0.0137
  Remission after steroid treatment            20   333/346   96.2(94.0--97.9)   23.76                    0.2057                      20     \<0.0001   0.072
  Relapse after steroid treatment              12   37/269    13.8(7.2--22.0)    34.91                    0.0003                      68.5   0.459      0.0015
  Repeated steroid treatment after relapse     8    58/59     95.8(89.8--99.3)   2.37                     0.9365                      0      0.0786     0.7643
  Remission after repeated steroid treatment   8    56/58     94.8(88.2--98.8)   4.28                     0.7466                      0      0.0786     0.6022

Discussion {#sec018}
==========

It has been nearly two decades since Yoshida *et al*. proposed the term autoimmune pancreatitis in 1995 \[[@pone.0130466.ref002]\] and AIP has now become a focus in research. Our study provided the comprehensive data of Chinese AIP patients. This study showed that the clinical features of AIP patients in China were consistent with the reports from other countries \[[@pone.0130466.ref006], [@pone.0130466.ref013], [@pone.0130466.ref017]\] except for the considerable proportion of pancreatic duct dilation (13.8%). Nearly one-third patients (29.7%) underwent surgeries due to suspected malignancy. The steroid regimen with an initial dose of 30 mg, 40 mg or 0.6mg/kg prednisone per day was effective in most patients with low rates of relapse and complications.

AIP is a rare disease and still a diagnostic challenge despite of increasing study in recent years. As a region with high prevalence of pancreatic disease, China would have a large amount of AIP patients. However, the concept of AIP has just been introduced in this decade and the first clinical report about Chinese AIP patients was published in 2008 \[[@pone.0130466.ref007]\]. In this study, we could only collect 706 patients from 26 articles, which suggested a large gap in the study of AIP between China and developed countries. Nowadays, several AIP diagnostic criteria including Japanese criteria, Mayo Clinic\'s HISORt criteria, Korean criteria, Asian diagnostic criteria and ICDC were proposed. Our study showed that the criteria above were adopted by different institutions in China, and 58.9% of AIP patients were diagnosed by Asian diagnostic criteria. Asian diagnostic criteria are simple and have good practicability, and may be more suitable for Chinese AIP patients due to similar ethnic background.

In ICDC, AIP is classified into two subtypes. Type 1 is recognized to be part of IgG4-related disease and type 2 is characterized by intraductal neutrophilic infiltration and no IgG4 elevation \[[@pone.0130466.ref004]\]. Type 2 only covered a proportion of 1% to 6% AIP patients in East Asia, while this proportion increased to 15% to 38% in Europe and North America \[[@pone.0130466.ref003], [@pone.0130466.ref018]--[@pone.0130466.ref020]\]. The present study revealed that type 2 AIP covered a proportion of 4.7% in China. This low proportion was consistent with the previous studies from Japan and Korea. Notably, type 2 AIP is much more difficult to be diagnosed because there is no specific serum marker and histological examination is always required. However, in clinical practice, an adequate specimen of the pancreas is not frequently available. In this study, 11.2% AIP patients received EUS-guided or CT-guided FNA but most of them only obtained cytology diagnosis. Several recent studies also showed the difficulty of obtaining adequate specimens for histopathological evaluation through FNA \[[@pone.0130466.ref021], [@pone.0130466.ref022]\]. From this perspective, the true prevalence of type 2 AIP in China may be underestimated. Due to the low proportion of type 2, our study mainly showed the features of type 1 AIP.

The clinical presentation of Chinese AIP was similar with previous reports from other countries \[[@pone.0130466.ref006], [@pone.0130466.ref013], [@pone.0130466.ref017]\]. The most common presentation were obstructive jaundice (pooled rate: 63.4%, 95%CI: 55.4%--71.0%) and abdominal symptoms (pooled rate: 62.3%, 95%CI: 52.4%--71.7%), both of which are nonspecific symptoms. Extrapancreatic lesion is an important diagnostic clue and evidence for AIP. In this study, we found that the proportions of biliary involvement, abdominal lymph nodes enlargement, swelling salivary gland, swelling lacrimal gland, retroperitoneal fibrosis, interstitial nephritis and interstitial lung disease were 65.9%, 19.7%, 12.0%, 2.0%, 3.4%, 4.6% and 3.0%, respectively. Biliary involvement, namely, IgG4-related sclerosing cholangitis is characterized by lower and upper bile duct stricture. Our study showed that the lower common bile duct stricture and hilar/intra hepatic bile ducts stricture covered 62.3% and 3.6% patients, respectively, which was similar with previous reports \[[@pone.0130466.ref023], [@pone.0130466.ref024]\]. Ulcerative colitis was more common seen in type 2 AIP than in type 1 \[[@pone.0130466.ref004]\]. In an international survey of AIP, ulcerative colitis was found in 15.6% (10/64) type 2 AIP patients and 1.3% (2/153) type 1 AIP patients \[[@pone.0130466.ref020]\]. Another study from United States showed that ulcerative colitis was present in 15.8% (3/19) with type 2 patients and 4.0% (2/50) with type 1 patients \[[@pone.0130466.ref025]\]. Our study also showed a low proportion of ulcerative colitis (pooled rate: 1.6%, 95%CI: 0.6%--2.9%) in Chinese AIP patients.

CT and MRI are main pancreatic parenchymal imaging modalities and play an essential role in the diagnosis of AIP. Our study showed some differences compared with ICDC. In ICDC, diffuse enlargement and segmental/focal enlargement are proposed to be typical and indeterminate findings, respectively \[[@pone.0130466.ref004]\]. However, in our study, 41.6% patients were classified into focal-type. The relatively high proportion of focal-type may be attributed to the fact that about one third patients obtained diagnosis of AIP after surgery and focal-type patients tends to receive surgery with suspect of malignancy, which led to potential selection bias. Moreover, pancreatic duct imaging was adopted by ICDC as an important diagnostic evidence for AIP and long and multiple strictures were recognized as the main manifestation, while dilation of the pancreatic duct was recognized as a rare manifestation to differentiate AIP from pancreatic cancer. In our study, about two-thirds patients showed stricture of pancreatic duct (pooled rate: 68.1%, 95%CI: 49.3%--84.3%) but dilatation was also found in 13.8% patients. In the previous study from our center \[[@pone.0130466.ref016]\], marked upstream dilatation (duct size \> 5 mm) upon stricture was seen in 16.0% (4/25) patients and in another report from China \[[@pone.0130466.ref009]\], dilation of pancreatic duct were found in 45.5% (10/22) type 1 AIP patients. Theoretically, the pathogenesis of AIP is different with ordinary chronic pancreatitis and dilated and irregularly shaped medium-sized and large ducts are rarely found in histology examination. Therefore, further study is needed to clarify the pancreatic duct imaging manifestation of Chinese AIP patients.

It was reported that the sensitivity of IgG4 elevation varies between 44%--95% in different settings \[[@pone.0130466.ref017], [@pone.0130466.ref026]\]. In our study, the level of serum IgG4 exceeds the upper limit of normal were observed in 86.0% patients in 9 (34.6%) articles, which indicated the similar diagnostic value for Chinese AIP patients. In the other 17 (65.4%) studies, IgG4 test could not be performed and the diagnosis of AIP depended on other evidences. However, IgG4 was the only recommended serological marker for type 1 AIP in the ICDC, performing IgG4 test would improve the accuracy and simplicity of diagnosing AIP.

Steroid treatment was given to nearly 80% AIP patients in China, including many patients who received surgery for suspected malignancy. AIP is highly responsive to steroid treatment. To date, although the ICDC defines the initial dose of steroid for induction of remission as 0.6 to 1 mg/kg per day, a steroid regimen has not been standardized, and there is no consensus on the duration of induction, the tapering schedule, and the optimal dose and duration of maintenance therapy \[[@pone.0130466.ref004], [@pone.0130466.ref027]\]. In China, an initial of 30mg or 40mg prednisone per day is adopted as the most commonly used regimen and our study showed the pooled remission rate as 96.2%, which proved the excellent response of Chinese AIP patients to steroid. Relapse after steroid treatment is an important issue. According to a multicenter, international survey, the relapse rate was 35.8% (245/684) after a long-term follow-up \[[@pone.0130466.ref028]\]. A study from Mayo Clinic showed that 44.8% (52/116) AIP patients experienced relapse during a median follow-up of 47 months \[[@pone.0130466.ref029]\]. In our study, the pooled rate of relapse was only 13.8% (37/269) with the mean follow-up time ranging from 12 to 45 months. A shorter follow-up time may explain the relatively low relapse rate in China. However, a report from Japan also showed the relapse was 12.5% after a mean follow- up of 43.5 months \[[@pone.0130466.ref030]\]. We think different steroid regimens may be another explanation. Maintenance steroid therapy, which could decrease relapse \[[@pone.0130466.ref031]\], was not adopted in most reports from Western countries but was always adopted in Eastern countries \[[@pone.0130466.ref032]\]. From this perspective, maintenance therapy may be a better choice for patients at high risk for relapse.

Limitations {#sec019}
===========

There are several limitations of this study. First, due to the nature of this systematic review, publication bias could not be avoided and significant heterogeneity existed in many aspects. We believed this is a suboptimal and feasible option to provide an overview of AIP in China, when a national study is not available. Second, type 1 and type 2 were clearly defined in ICDC in 2011; however, not all enrolled studies adopted these criteria, so we could not exactly distinguish type 1 and type 2 AIP. However, with low proportion of type 2, our study mainly showed the features of Chinese type 1 AIP patients.

Conclusions {#sec020}
===========

In conclusion, type 1 is the predominant type of Chinese AIP patients and the clinical features, diagnostic modalities and therapeutic regimen were fundamentally similar with those in other countries. Knowledge of AIP should be more widespread to avoid unnecessary surgery.
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